Skip to main content

ORIGINAL RESEARCH article

Front. Neurol.
Sec. Dementia and Neurodegenerative Diseases
Volume 15 - 2024 | doi: 10.3389/fneur.2024.1422681

CAPS: A simple clinical tool for β-amyloid positivity prediction in clinical Alzheimer Syndrome

Provisionally accepted
Durjoy Lahiri Durjoy Lahiri 1,2Bruna Seixas-Lima Bruna Seixas-Lima 1,2Carlos Roncero Carlos Roncero 1,2Nicolaas P. Verhoeff Nicolaas P. Verhoeff 1,3Morris FReedman Morris FReedman 1,3Sarmad Al-Shaama Sarmad Al-Shaama 1,3Howard Chertkow Howard Chertkow 1,2,3*
  • 1 University of Toronto, Toronto, Canada
  • 2 Rotman Research Institute (RRI), Toronto, Ontario, Canada
  • 3 Baycrest Hospital, Toronto, Ontario, Canada

The final, formatted version of the article will be published soon.

    With the advent of anti-β-amyloid therapies, clinical distinction between Aβ+ and Aβ-in cognitive impairment is becoming increasingly important for stratifying referral and better utilization of biomarker assays. METHODS: Cognitive profile, rate of decline, neuropsychiatric inventory questionnaire (NPI-Q) and imaging characteristics were collected from 52 subjects with possible/ probable AD. RESULTS: Participants with Aβ+ status had lower baseline MMSE scores (24.50 vs 26.85, p=0.009) and higher total NPI-Q scores (2.73 vs 1.18, p<.001). NPI-Q score was found to be the only independent predictor for β-amyloid positivity (p=.008). A simple scoring system, namely CAPS, was developed by using the following parameters: NPI-Q, rapidity of cognitive decline, and white matter microangiopathy. Data from 48 participants were included in the analysis of accuracy of CAPS. CAP Score of 3 or 4 successfully classified Aβ+ individuals in 86.7% cases. DISCUSSION: CAPS is a simple clinical tool for use in primary care and memory clinic settings to predict β-amyloid positivity in individuals with clinical Alzheimer Syndrome can potentially facilitate referral for Anti Aβ therapies.

    Keywords: Alzheimer, clinical, CAPS, early diagnosis, Amyloid - beta

    Received: 24 Apr 2024; Accepted: 29 Jul 2024.

    Copyright: © 2024 Lahiri, Seixas-Lima, Roncero, Verhoeff, FReedman, Al-Shaama and Chertkow. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Howard Chertkow, University of Toronto, Toronto, Canada

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.